{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:05:52Z","timestamp":1793739952354,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018628","name":"Scientific Research Foundation of Education Department of Anhui Province of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.taap.2026.117777","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:20:01Z","timestamp":1772641201000},"page":"117777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MiR-29a\/DNMT3A axis participates in Dihydroartemisinin's suppression on lung adenocarcinoma: Implications for overcoming acquired resistance to EGFR-TKIs"],"prefix":"10.1016","volume":"511","author":[{"given":"Yayu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.taap.2026.117777_bb0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0165-6147(99)01302-4","article-title":"Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication","volume":"20","author":"van Agtmael","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2026.117777_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107706","article-title":"Artemisinins as a novel anti-cancer therapy: targeting a global cancer pandemic through drug repurposing","volume":"216","author":"Augustin","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.taap.2026.117777_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105701","article-title":"Dihydroartemisinin overcomes the resistance to osimertinib in egfr-mutant non-small-cell lung cancer","volume":"170","author":"Cai","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"22","key":"10.1016\/j.taap.2026.117777_bb0020","doi-asserted-by":"crossref","first-page":"651","DOI":"10.21037\/atm.2019.10.80","article-title":"Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma","volume":"7","author":"Chaib","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"10.1016\/j.taap.2026.117777_bb0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/epi.28324","article-title":"The de novo dna methyltransferase dnmt3a in development and cancer","volume":"9","author":"Chen","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.taap.2026.117777_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116572","article-title":"Curcumin regulates pulmonary extracellular matrix remodeling and mitochondrial function to attenuate pulmonary fibrosis by regulating the mir-29a-3p\/dnmt3a axis","volume":"174","author":"Cheng","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.taap.2026.117777_bb0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/CAD.0000000000000469","article-title":"Effect of dihydroartemisinin on uhrf1 gene expression in human prostate cancer pc-3 cells","volume":"28","author":"Du","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"40","key":"10.1016\/j.taap.2026.117777_bb0040","doi-asserted-by":"crossref","first-page":"15805","DOI":"10.1073\/pnas.0707628104","article-title":"Microrna-29 family reverts aberrant methylation in lung cancer by targeting dna methyltransferases 3a and 3b","volume":"104","author":"Fabbri","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2026.117777_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1137384","article-title":"Monitoring egfr-lung cancer evolution: a possible beginning of a \"methylation era\" in tki resistance prediction","volume":"13","author":"Fabrizio","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.taap.2026.117777_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175746","article-title":"B7-h3 but not pd-l1 is involved in the antitumor effects of dihydroartemisinin in non-small cell lung cancer","volume":"950","author":"Hu","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.taap.2026.117777_bb0055","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood-2014-06-585273","article-title":"Mir-29a maintains mouse hematopoietic stem cell self-renewal by regulating dnmt3a","volume":"125","author":"Hu","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.taap.2026.117777_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/2159-8290.CD-21-0560","article-title":"Systematic profiling of DNMT3A variants reveals protein instability mediated by the DCAF8 E3 ubiquitin ligase adaptor","volume":"12","author":"Huang","year":"2022","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.taap.2026.117777_bb0065","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1007\/s00277-024-05874-x","article-title":"Dnmt3a-r882: a mutation with many paradoxes","volume":"103","author":"Jafari","year":"2024","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.taap.2026.117777_bb0070","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/kjm2.12684","article-title":"Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ros-dependent apoptosis and ferroptosis","volume":"39","author":"Lai","year":"2023","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"1","key":"10.1016\/j.taap.2026.117777_bb0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41392-024-01981-3","article-title":"Mechanism exploration and model construction for small cell transformation in egfr-mutant lung adenocarcinomas","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"21","key":"10.1016\/j.taap.2026.117777_bb0080","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s00018-012-1124-0","article-title":"Microrna-29 in the adaptive immune system: setting the threshold","volume":"69","author":"Liston","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.taap.2026.117777_bb0085","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-17-1169","article-title":"Downregulation of dnmt3a by mir-708-5p inhibits lung cancer stem cell-like phenotypes through repressing wnt\/beta-catenin signaling","volume":"24","author":"Liu","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10454","key":"10.1016\/j.taap.2026.117777_bb0090","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.taap.2026.117777_bb0095","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.3390\/ijms140714647","article-title":"Mir-29 represses the activities of dna methyltransferases and dna demethylases","volume":"14","author":"Morita","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2026.117777_bb0100","series-title":"Lung Adenocarcinoma","author":"Myers","year":"2025"},{"issue":"1","key":"10.1016\/j.taap.2026.117777_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/acscentsci.9b00874","article-title":"Dna methylation bisubstrate inhibitors are fast-acting drugs active against artemisinin-resistant plasmodium falciparum parasites","volume":"6","author":"Nardella","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.taap.2026.117777_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2025.102033","article-title":"Dnmt3a triggers tumorigenesis of non-small cell lung cancer through regulation of slit2 methylation and slit2-mediated macrophage m1\/m2 polarization","volume":"82","author":"Ni","year":"2025","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.taap.2026.117777_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151854","article-title":"Exploring combinations of dihydroartemisinin for cancer therapy: a comprehensive review","volume":"765","author":"Rani","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.taap.2026.117777_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102440","article-title":"Epidrugs as promising tools to eliminate Plasmodium falciparum artemisinin-resistant and quiescent parasites","volume":"15","author":"Reyser","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.taap.2026.117777_bb0125","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.annonc.2025.06.003","article-title":"Dna methyltransferase 3a (dnmt3a) mutations and pd-(l)1 blockade efficacy in non-small-cell lung cancer","volume":"36","author":"Ricciuti","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.taap.2026.117777_bb0130","doi-asserted-by":"crossref","first-page":"20243","DOI":"10.1038\/s41598-020-76791-y","article-title":"Comprehensive genomic profile of chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib\/gefitinib","volume":"10","author":"Shang","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.taap.2026.117777_bb0135","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.taap.2026.117777_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188967","article-title":"20 years since the approval of first egfr-tki, gefitinib: insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"10.1016\/j.taap.2026.117777_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155222","article-title":"Emerging role of tumor suppressing micrornas as therapeutics in managing non-small cell lung cancer","volume":"256","author":"Singh","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"16","key":"10.1016\/j.taap.2026.117777_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29163886","article-title":"Artemisinin and its derivatives as potential anticancer agents","volume":"29","author":"Wen","year":"2024","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.taap.2026.117777_bb0155","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1016\/j.apsb.2024.08.025","article-title":"Dnmt3a loss drives a hif-1-dependent synthetic lethality to hdac6 inhibition in non-small cell lung cancer","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.taap.2026.117777_bb0160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41416-024-02772-x","article-title":"Kdm1a, a potent and selective target, for the treatment of dnmt3a-deficient non-small cell lung cancer","volume":"131","author":"Zhao","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.taap.2026.117777_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of egfr-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26000736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26000736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:13:49Z","timestamp":1784812429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X26000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0041008X26000736"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2026.117777","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-29a\/DNMT3A axis participates in Dihydroartemisinin's suppression on lung adenocarcinoma: Implications for overcoming acquired resistance to EGFR-TKIs","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2026.117777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117777"}}